Most opioid recovery apps lack evidence, safety oversight, study finds

Researchers examining the landscape of smartphone apps and digital tools designed to help people recover from opioid addiction have uncovered a troubling gap: the vast majority of apps available for download have never been tested in rigorous scientific studies, and most lack any form of regulatory approval. The finding emerges from a comprehensive review published in PLOS Digital Health that surveyed both the published research on digital recovery tools and the commercial marketplace where people actually search for help.

The review identified 34 published studies examining digital interventions for opioid use disorder, most of them small pilot projects that showed the tools were acceptable to users and feasible to implement. But when researchers looked at the 21 apps and digital tools currently available on commercial app stores, they found a stark mismatch with the evidence base. Only eight of those 21 apps had any published research supporting their use. Seventeen apps—81 percent of what's available to download—had neither FDA approval nor peer-reviewed evidence behind them, despite being marketed to people struggling with addiction and facing genuine risk of overdose death.

This matters because the stakes are high. In 2022 alone, more than 100,000 people in the United States died from opioid overdoses. Globally, opioid use disorder has become the fastest-growing substance use disorder, rising from 47 percent to 53 percent of all drug use disorders between 1990 and 2017. The condition carries enormous personal weight: people living with opioid addiction face disrupted mental and physical health, fractured relationships, employment instability, and housing insecurity. About 60 percent of people with opioid use disorder also have a co-occurring mental illness. The economic toll is staggering—the U.S. alone spent an estimated $1.02 trillion on opioid-related costs in 2017, with more than half that amount reflecting lost productivity and lives lost to overdose.

Medication-based treatment—primarily buprenorphine and methadone—has strong evidence behind it and significantly reduces overdose risk, suicide, and infectious disease transmission. Yet access remains limited, with only about 20 to 30 percent of Americans with opioid use disorder actually receiving medication-assisted treatment. Digital tools have been proposed as a way to bridge that gap, offering flexible, accessible support that could help people stay engaged with treatment and manage cravings between appointments. The research reviewed in this study suggests that people do find these apps acceptable and are willing to use them. But the efficacy data are mixed. Some studies showed benefits for abstinence or medication adherence; others did not. No single intervention emerged as clearly superior.

Beyond the question of whether these tools actually work lies a more immediate concern: safety and privacy. The review highlights critical gaps that have received little attention in published research. In many jurisdictions, personal drug use remains illegal, which means data collected within an app could potentially be subpoenaed by law enforcement. Yet most apps provide no clear information about whether the data they collect is protected as health information or vulnerable to legal discovery. Medical professionals face complex ethical dilemmas too. If a client logs substance use while driving and a clinician sees that entry, does mandatory reporting of impaired driving apply? If an app crashes during a crisis or a clinician is unavailable outside business hours, who bears responsibility for harm? These questions remain largely unanswered.

The review also found that most research on digital opioid recovery tools has been conducted with predominantly white male populations, raising questions about whether findings apply to women, people of color, and people experiencing homelessness—groups that face structural barriers to opioid treatment and may have different needs. Most studies focused on supporting medication adherence rather than addressing the broader dimensions of recovery: cravings, self-efficacy, social connection, and housing stability.

The authors recommend that regulatory bodies expand their definition of what constitutes a medical device to include any app marketed to clinical populations, regardless of whether developers frame it as a wellness tool or a treatment. They also call for clearer guidelines around privacy protections, safety protocols, and the medical-legal responsibilities of both app developers and clinicians. For now, they advise clinical caution: if a clinician is considering recommending an app to a patient, that app should have undergone privacy evaluation, demonstrated safety measures, and ideally shown efficacy in a rigorous trial. The field of digital health for opioid recovery, the authors conclude, remains in its infancy—promising in some ways, but far from ready for widespread deployment without substantial additional work on evidence, safety, and equity.